GlassScriptPhysician profile
Erin M Galbraith
NPI 1750304259
$1,382.12
in general payments reported to CMS, 2019-2025
21 companies · $383 in 2025
The $383 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $15.73 · 2021: $43.16 · 2022: $99.51 · 2023: $167 · 2024: $459 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $265.25 | 2019-2024 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $138.48 | 2024 | Opsumit, Uptravi |
| Abiomed | $136.65 | 2024-2025 | Impella |
| Edwards Lifesciences Corporation | $118.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $107.50 | 2023-2025 | |
| Biotronik INC. | $79.00 | 2023 | Acticor 7 Vr-T Dx |
| Shockwave Medical, INC | $68.15 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $68.06 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $63.03 | 2024-2025 | Camzyos, Eliquis |
| Stryker Corporation | $60.56 | 2022 | |
| Heartflow, INC. | $46.65 | 2024 | |
| Amgen INC. | $36.08 | 2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.18 | 2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $31.13 | 2024 | Arcalyst |
| Innovation Technologies INC | $25.88 | 2025 | Irrisept |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $20.67 | 2019 | |
| Cvrx, INC. | $20.12 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $18.75 | 2024 | Farxiga |
| Medtronic, INC. | $16.73 | 2023 | Onyx Frontier |
| Cardiva Medical, INC. | $14.68 | 2023 | Cardiva Vascade 6/7f Vcs |
| Philips North America LLC | $12.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Galbraith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.